The acute reaction to an overdosage of BLEO-cellmycin would probably include hypotension, fever, rapid pulse and general symptoms of shock.
Treatment is purely symptomatic. In the event of respiratory complications the patient should be treated with a corticosteroid and a broad-spectrum antibiotic. There is no specific antidote to BLEO-cellmycin.
BLEO-cellmycin is contra-indicated in patients with acute pulmonary infection or chest X-ray findings suggesting diffuse fibrotic changes or greatly reduced lung function.
Patients with a past history of hypersensitivity or idiosyncratic reaction to an analogue of BLEO-cellmycin.
BLEO-cellmycin solution should not be mixed with solutions of essential amino acids, riboflavine, ascorbic acid, dexamethasone, aminophylline or frusemide.
The most frequently observed adverse reactions in 1613 patients receiving BLEO-cellmycin were pulmonary manifestations such as interstitial pneumonia or pulmonary fibrosis (10.2%), sclerosis of skin, pigmentation (40.6%), fever and rigors (39.8%), alopecia (29.5%), anorexia and weight decrease (28.7%), general malaise (16.0%), nausea and vomiting (14.6%), stomatitis (13.3%) and nail changes (11.2%).
Tabulated Summary of Adverse Reactions with BLEO-cellmycin:
The following adverse reactions have been reported with BLEO-cellmycin during clinical studies and from post-marketing experience. They are listed below by system organ class and frequency (very common > 1/10; common > 1/100 to < 1/10; uncommon >1/1,000 to <1/100; not known (cannot be estimated from available data)).
| System Organ Class | Adverse Reaction by Frequency | |||
|
| Very Common >1/10 | Common > 1/100 to < 1/10 | Uncommon > 1/1,000 to < 1/100 | Not known (cannot be estimated from available data) |
| Infections and infestations | Sepsis | |||
| Neoplasms, Benign, Malignant and Unspecified (including Cysts and Polyps) | Tumour pain | |||
| Blood and lymphatic system disorders | Leukopenia | Pancytopenia; thrombocytopenia; anaemia; neutropenia | ||
| Metabolism and Nutrition disorders | Decreased appetite | |||
| Nervous system disorders | Headache | Dizziness | ||
| Cardiac disorders | Myocardial infarction | |||
| Vascular disorders | Haemorrhage | Shock; vein wall hypertrophy; venous stenosis | Hypotension; injection site thrombosis*; Raynaud's phenomenon; embolism; thrombosis; peripheral ischaemia; cerebral infarction | |
| Respiratory, thoracic and mediastinal disorders | Interstitial pneumonia; pulmonary fibrosis | |||
| Gastrointestinal disorders | Weight decreased; nausea; vomiting; stomatitis | Angular cheilitis | Diarrhoea | |
| Hepatobilliary disorders | Hepatocellular injury | |||
| Skin and subcutaneous tissue | Alopecia; skin hypertrophy; pigmentation disorder; nail deformation; nail discolouration; flagellate dermatitis | Rash; urticaria; exfoliative dermatitis | ||
| Musculoskeletal and connective tissue disorders | Scleroderma | |||
| Renal and Urinary disorders | Oliguria; dysuria; pollakiuria; urinary retention; polyuria; feeling of residual urine | |||
| General disorders and administration site conditions | Pyrexia; chills; malaise | Injection site induration | Fatigue; injection site pain; chest pain | |
* Following intravenous administration
Like most cytotoxic agents BLEO-cellmycin can give rise to both immediate and to delayed toxic effects. The most immediate effect is fever on the day of injection. Fever may develop with a lag time of 4-5 hours or more after the administration of this drug. Because a dose- response relation exists between the fever and dose at a given time, if the fever is severe, appropriate measures should be taken such as administering a reduced dose at shorter intervals, or antihistaminic and antipyretic agents before and/or after administration of this drug.
The majority of patients who receive a full course of BLEO-cellmycin develop lesions of the skin or oral mucosa. Induration, hyperkeratosis, reddening, tenderness and swelling of the tips of the fingers, ridging of the nails, bulla formation over pressure points such as elbows, loss of hair and stomatitis are rarely serious and usually disappear soon after completion of the course.
The most serious delayed effect is interstitial pneumonia, which may develop during, or occasionally after, a course of treatment. This condition may sometimes develop into fatal pulmonary fibrosis, although such an occurrence is rare at recommended doses. Previous or concurrent radiotherapy to the chest is an important factor in increasing the incidence and severity of lung toxicity.
A few cases of acute fulminant reactions with hyperpyrexia and cardiorespiratory collapse have been observed after intravenous injections of doses higher than those recommended. Hypotension, hyperpyrexia and drug-related deaths have been reported rarely following intra-cavitary instillation of BLEO-cellmycin.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Animal experiences have revealed that BLEO-cellmycin, like most cytotoxics, may have teratogenic and carcinogenic potential.
BLEO-cellmycin has been reported to cause fibrosarcoma and renal carcinoma in a laboratory animal (rat) administered subcutaneously.
BLEO-cellmycin has been reported to cause foetal malformation in laboratory animals (mice and rats).
a. Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesophagus, external genitalia, cervix or skin. Well differentiated tumours usually respond better than anaplastic ones.
b. Hodgkin's disease and other malignant lymphomas, including mycosis fungoides.
c. Testicular teratoma
d. Malignant effusions of serous cavities.
e. Secondary indications in which BLEO-cellmycin has been shown to be of some value (alone or in combination with other drugs) include metastatic malignant melanoma, carcinoma of the thyroid, lung and bladder.
ATC code: LO1D C01, other cytotoxic antibiotics
BLEO-cellmycin is a basic, water-soluble glycopeptide with cytotoxic activity. The mechanism of action of BLEO-cellmycin is believed to involve single-strand scission of DNA, leading to inhibition of cell division, of growth and of DNA synthesis in tumour cells.
Apart from its antibacterial and antitumour properties, BLEO-cellmycin is relatively free from biological activity. When injected intravenously it may have a histamine-like effect on blood pressure and may cause a rise in body temperature.
BLEO-cellmycin is administered parenterally. After intravenous (IV) administration of a bolus dose of 15 x 103 IU/m2 body surface, peak concentrations of 1 to 10 IU are achieved in plasma. Following the intramuscular (IM) injection of 15 x 103 IU peak plasma concentrations of about 1 IU/ml have been reported. The peak plasma concentration is reached 30 minutes after an IM injection. Continuous infusion of BLEO-cellmycin 30 x 103 IU daily, for 4 to 5 days, resulted in an average steady state plasma concentration of 100-300 milli IU/ml. After IV injections of BLEO-cellmycin in a dose of 15 x 103 IU/m2 body surface, the area under the serum concentration curve is, on average, 300 milli IU x min x ml-1.
BLEO-cellmycin is only bound to plasma proteins to a slight extent. BLEO-cellmycin is rapidly distributed in body tissues, with the highest concentrations in skin, lungs, peritoneum and lymph. Low concentrations are seen in the bone marrow. BLEO-cellmycin could not be detected in cerebrospinal fluid after intravenous injection. BLEO-cellmycin appears to cross the placental barrier.
The mechanism for bio-transformation is not yet fully known. Inactivation takes place during enzymatic breakdown by BLEO-cellmycin hydrolase, primarily in plasma, liver and other organs and, to a much lesser degree, in skin and lungs. When BLEO-cellmycin was administered as an IV bolus injection in a dose of 15 x 103 IU/m2 body surface, initial and terminal half-lives were 0.5 and 4 hours respectively. Given as a continuous intravenous infusion in a dose of 30 x 103 IU daily for 4 to 5 days BLEO-cellmycin disappears from plasma with initial and terminal half-lives of about 1.3 hours and 9 hours, respectively. About two thirds of the administered drug is excreted unchanged in the urine, probably by glomerular filtration. Approximately 50% is recovered in the urine in the 24 hours following an IV or IM injection. The rate of excretion, therefore, is highly influenced by renal function; concentrations in plasma are greatly elevated if usual doses are given to patients with renal impairment with only up to 20% excreted in 24 hours. Observations indicate that it is difficult to eliminate BLEO-cellmycin from the body by dialysis.
Pulmonary toxicity of BLEO-cellmycin is both dose-related and age-related. It may also occur when lower doses are administered, especially in elderly patients, patients with reduced kidney function, pre-existing lung disease, previous or concurrent radiotherapy to the chest and in patients who need administration of oxygen. It is significantly enhanced by thoracic radiation and by hyperoxia used during surgical anaesthesia.
The earliest symptom associated with pulmonary toxicity of BLEO-cellmycin is dyspnoea. Fine rales are the earliest sign. If pulmonary changes are noted, treatment should be discontinued until it can be determined if they are drug related. Patients should be treated with broad spectrum antibiotics and corticosteroids.
Patients undergoing treatment with BLEO-cellmycin should have chest X-rays weekly. These should continue to be taken for up to 4 weeks after completion of the course and patients should be kept under clinical review for approximately 2 months. If breathlessness or lung infiltrates appear, not obviously attributable to tumour or to co-existent lung disease, administration of the drug must be stopped immediately and patients should be treated with a corticosteroid and a broad spectrum antibiotic. High oxygen concentrations should be used with caution in these cases.
Lung function tests which use 100% oxygen should not be used in patients who have been treated with BLEO-cellmycin. Lung function tests using less than 21% oxygen are recommended as an alternative.
When BLEO-cellmycin has been administered pre-operatively, reduced oxygen concentrations should be used during operation and post operatively.
Patients should be carefully monitored under the following conditions and BLEO-cellmycin dosage should be reduced or prolong the dose interval based on clinical observation of the patient: These clinical conditions include the following:
- Patients treated previously or concurrently with radiation to the chest may develop more frequent or severe toxicity.
- Use with caution in patients with significant renal impairment as clearance may be reduced and toxicity increased.
- Use with caution in patients with severe heart disease or hepatic dysfunction as toxicity may be increased.
- Use with caution in patients with varicella as fatal systematic dysfunctions may occur.
Because BLEO-cellmycin treatment may give rise to shock, if any abnormalities appear, withdraw BLEO-cellmycin immediately, and take appropriate measures. (Because shock is likely to develop in patients with malignant lymphomas at the 1st - 2nd administration, you may start this drug treatment with lower dose and after establishing that no acute reactions to the drug occur, increase the dose to the usual level).
With long-term administration of BLEO-cellmycin, peplomycin or other analogies of BLEO-cellmycin, toxicity is thought to be additive, thus administration must be performed with care.
Attention should be paid to the appearance or exacerbation of infection and any bleeding tendency.
In adults or adolescents capable of reproduction, effects on the sexual glands should be considered.
Intravenous administration
Vascular pain may occur, therefore, it is important to pay due attention to concentration of the injection and administration rate. Give intravenously as slowly as possible.
Intramuscular administration
Avoid repeated injections at the same site and innervated sites, particularly if administering to paediatrics. If insertion of the injection needle evokes intense pain or if blood flows back into the syringe, withdraw the needle immediately and inject at a different site.
This depends on the patient's condition and should be considered in co-operation with the doctor.
Adults
Routes of administration
BLEO-cellmycin is usually administered intramuscularly but may be given intravenously (bolus or drip), intra-arterially, intrapleurally or intraperitoneally as a solution in physiological saline.
Local injection directly into the tumour may occasionally be indicated.
Recommended dose and dosage schedules
Squamous cell carcinoma and testicular teratoma:
Used alone the normal dosage is 15 x 103 IU (1 vial) three times a week or 30 x 103 IU (2 vials) twice a week, either intramuscularly or intravenously. Treatment may continue on consecutive weeks, or more usually at intervals of 3-4 weeks, up to a lifetime cumulative dose of 360 x 103 IU. Continuous intravenous infusion at a rate of 15 x 103 IU (1 vial) per 24 hours for up to 10 days, or 30 x 103 IU (2 vials) per 24 hours for up to 5 days may produce a therapeutic effect more rapidly. The development of stomatitis is the most useful guide to the determination of individual tolerance of maximum therapeutic response. The dose may need to be adjusted when BLEO-cellmycin is used in combination chemotherapy. Use in elderly or children - see below.
Malignant lymphomas:
Used alone the recommended dosage regime is 15 x 103 IU (1 vial) once or twice a week, intramuscularly, to a total dose of 225 x 103 IU (15 vials). Lifetime cumulative dose should not exceed 360 x 103 IU. Dosage should be reduced in the elderly. The dose may need to be adjusted when BLEO-cellmycin is used in combination chemotherapy. Use in elderly or children - see below.
Malignant effusions:
After drainage of the affected serous cavity 60 x 103 IU (4 vials) BLEO-cellmycin dissolved in 100 ml physiological saline is introduced via the drainage needle or cannula. After instillation, the drainage needle or cannula may be withdrawn. Administration may be repeated if necessary subject to a lifetime cumulative dose of 360 x 103 IU (about 24 vials). Use in the elderly or children - see below.
Combination therapy:
BLEO-cellmycin is commonly used in conjunction with radiotherapy, particularly in treatment of cancer of the head and neck region. Such a combination may enhance mucosal reactions if full doses of both forms of treatment are used and BLEO-cellmycin dosage may require reduction, e.g. to 5 x 103 IU at the time of each radiotherapy fraction five days a week. BLEO-cellmycin is frequently used as one of the drugs in multiple chemotherapy regimes (e.g. squamous cell carcinoma, testicular teratoma, lymphoma). The mucosal toxicity of BLEO-cellmycin should be borne in mind in the selection and dosage of drugs with similar toxic potential used in such combinations.
Elderly Patients:
The total dose of BLEO-cellmycin used in the treatment of squamous cell carcinoma, testicular teratoma or malignant effusions should be reduced as indicated below:
| Age in years | Total Dose (IU) | Dose per week (IU) |
| 80 and over | 100 x 103 | 15 x 103 |
| 70 - 79 | 150 - 200 x 103 | 30 x 103 |
| 60 - 69 | 200 - 300 x 103 | 30 - 60 x 103 |
Paediatric population
Administration of BLEO-cellmycin to paediatrics should take place only under exceptional circumstances and in special centres. The dosage should be based on that recommended for adults and adjusted to body surface area or body weight.
Reduced kidney function
With serum creatinine values of 2-4 mg/dL, it is recommended to half the above dosages. With serum creatinine above 4 mg/dL, a further reduction in dose is indicated.
Preparation of solution
For intramuscular injections the required dose is dissolved in up to 5 ml of suitable solvents such as physiological saline. If pain occurs at the site of injection a 1% solution of lignocaine may be used as a solvent.
For intravenous injections the dose required is dissolved in 5-200 ml of physiological saline and injected slowly or added to the reservoir of a running intravenous infusion. For intra-arterial administration a slow infusion in physiological saline is used. For intra-cavitary injection 60 x 103 IU is dissolved in 100 ml of normal saline.
For local injections BLEO-cellmycin is dissolved in physiological saline to make a 1-3 x 103 IU/ml solution.
BLEO-cellmycin should be handled with care. Precautions should be taken to avoid BLEO-cellmycin coming into contact with skin, mucous membranes or eyes, but in the event of contamination the affected part should be washed with water.
